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Abstract
B cells play an important role in the pathogenesis of systemic
lupus erythematosus (SLE), so the safety and activity of anti-B
cell immunotherapy with the humanized anti-CD22 antibody
epratuzumab was evaluated in SLE patients. An open-label,
single-center study of 14 patients with moderately active SLE
(total British Isles Lupus Assessment Group (BILAG) score 6 to
12) was conducted. Patients received 360 mg/m2 epratuzumab
intravenously every 2 weeks for 4 doses with analgesic/
antihistamine premedication (but no steroids) prior to each
dose. Evaluations at 6, 10, 18 and 32 weeks (6 months post-
treatment) follow-up included safety, SLE activity (BILAG
score), blood levels of epratuzumab, B and T cells,
immunoglobulins, and human anti-epratuzumab antibody
(HAHA) titers. Total BILAG scores decreased by ≥ 50% in all 14
patients at some point during the study (including 77% with a ≥
50% decrease at 6 weeks), with 92% having decreases of
various amounts continuing to at least 18 weeks (where 38%
showed a ≥ 50% decrease). Almost all patients (93%)
experienced improvements in at least one BILAG B- or C-level
disease activity at 6, 10 and 18 weeks. Additionally, 3 patients
with multiple BILAG B involvement at baseline had completely
resolved all B-level disease activities by 18 weeks. Epratuzumab
was well tolerated, with a median infusion time of 32 minutes.
Drug serum levels were measurable for at least 4 weeks post-
treatment and detectable in most samples at 18 weeks. B cell
levels decreased by an average of 35% at 18 weeks and
remained depressed at 6 months post-treatment. Changes in
routine safety laboratory tests were infrequent and without any
consistent pattern, and there was no evidence of
immunogenicity or significant changes in T cells,
immunoglobulins, or autoantibody levels. In patients with mild to
moderate active lupus, 360 mg/m2  epratuzumab was well
tolerated, with evidence of clinical improvement after the first
infusion and durable clinical benefit across most body systems.
As such, multicenter controlled studies are being conducted in
broader patient populations.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic autoim-
mune disease that can involve many organ systems [1]. In
Europe and the United States, estimates of the number of
affected individuals range from 24 to 65 cases per 100,000
people [1,2]. The clinical course of SLE is episodic, with recur-
ring activity flares causing increasing disability and organ dam-
age. Cyclophosphamide, azathoprine, and corticosteroids
remain important for long-term management of most patients
having active disease, and even those in clinical remission [1].
Despite the important advances made with these drugs, espe-
cially cyclophosphamide, in controlling lupus disease activity,
they have considerable cytotoxicity and cause, for example,
bone marrow depression, ovarian failure, enhanced risk of
bladder cancer, as well as the known side effects of long-term
systemic corticosteroid therapy. As such, there continues to
be a need for the development of targeted and less toxic ther-
apies.
BCR = B cell antigen receptor; BILAG = British Isles Lupus Assessment Group; HACA = human anti-chimeric antibody; HAHA = human anti-human 
(epratuzumab) antibody; NCI CTC = National Cancer Institute Common Toxicity Criteria; NHL = non-Hodgkin lymphoma; SLE = systemic lupus ery-
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Specific autoantibodies against nuclear, cytoplasmic, and
membrane antigens remain the serological hallmark of SLE.
While lymphopenia is common, there is an increase in the level
of activated B cells [3,4] and characteristic alterations of B cell
subpopulations [5,6] that may be driven by extrinsic or intrinsic
factors. B cells appear to have a key role in the activation of the
immune system, in particular through the production of
cytokines and by serving as antigen-presenting cells (reviewed
recently in [7] ). Although B cell activation can occur inde-
pendently of T cell help in lupus, a substantial fraction of B
cells is activated in a T cell dependent manner [8-10], as dem-
onstrated by isotype switching and affinity maturation of B
cells [11,12] and enhanced CD154-CD40 interactions [13].
Useful insight into the pathogenesis of lupus has been
obtained with animal models. MRL/lpr mice spontaneously
develop a lupus-like autoimmune disease in an age-dependent
manner, including autoantibody production, arthritis, skin
lesions, and severe nephritis, which usually leads to early
demise from renal failure [14]. When rendered B cell deficient,
they no longer develop nephritis, mononuclear infiltrates are
no longer detectable in the kidneys or skin, the number of acti-
vated memory T cells are markedly reduced, and infusions of
pooled serum from diseased MRL/lpr mice lead to glomerular
antibody deposition, but not the development of renal disease
[15,16]. However, when reconstituted with B cells not able to
secrete circulating antibodies, they develop nephritis and vas-
culitis [17]. As such, it appears that B cells play a direct role in
promoting disease beyond the production of autoantibodies
[18].
Depleting B cells with anti-CD20 monoclonal antibodies has
emerged as a potentially new therapeutic strategy for certain
autoimmune diseases. The chimeric monoclonal antibody
rituximab depletes B cells by targeting the pan-B cell surface
antigen CD20. Preliminary experience with rituximab in about
100 patients with SLE (recently reviewed in [7] ) and other
autoimmune diseases has been encouraging [6,19-22].
Due to the central role of B cells in the pathogenesis of certain
autoimmune diseases, targeted anti-B cell immunotherapies
would be expected to offer therapeutic value in the setting of
SLE. In addition to CD20, another unique target is CD22, a
135 kDa glycoprotein that is a B-lymphocyte-restricted mem-
ber of the immunoglobulin superfamily, and a member of the
sialoadhesin family of adhesion molecules that regulate B cell
activation and interaction with T cells [23-27]. CD22 has
seven extracellular domains and is rapidly internalized when
cross-linked with its natural ligand, producing a potent co-
stimulatory signal in primary B cells [25,28-30]. The function
of CD22 in cell signaling is suggested by six tyrosine and three
inhibitory domain sequences in the intra-cellular cytoplasmic
tail. These inhibitory domains are phosphorylated by the non-
receptor kinase Lyn upon B cell antigen receptor (BCR) acti-
vation by IgM ligation, leading to the activation and recruitment
of SHP-1 phosphatase [31,32]. SHP-1 is a tyrosine phos-
phatase that negatively regulates several intracellular signaling
pathways, including the calcium pathway, through dephos-
phorylation of signaling intermediates, such as Lyn and Syk.
CD22 is first expressed in the cytoplasm of pro-B and pre-B
cells, and then on the surface of B cells as they mature, with
expression ceasing with B cell differentiation into plasma cells
[23]. Studies in CD22-deficient mice and in CD22-negative
cell lines have shown an increase in calcium response to BCR
ligation [33-36], indicating that CD22 inhibition of BCR sign-
aling is achieved through the mechanism of controlling cal-
cium efflux in B cells. It has been reported that this effect of
CD22 is mediated by potentiation of plasma membrane cal-
cium-ATPase and requires SHP-1 [37]. Animal experiments
indicate that CD22 plays a key role in B cell development and
survival, with CD22-deficient mice having reduced numbers of
mature B cells in the bone marrow and circulation, and with the
B cells also having a shorter life span and enhanced apoptosis
[31].
Therefore, CD22 is an attractive molecular target for therapy
because of its restricted expression; it is not exposed on
embryonic stem or pre-B cells, nor is it normally shed from the
surface of antigen-bearing cells. Initially, a mouse monoclonal
antibody (mLL2, formerly EPB-2) was developed and charac-
terized that specifically binds to the third domain of CD22
[38,39]. Immunohistological evaluation revealed that it recog-
nized B cells within the spleen and lymph nodes, but did not
react with antigen unrelated to B cells in normal and solid
tumor tissue specimens, and flow cytometry showed no reac-
tivity with platelets, red blood cells, monocytes, and granulo-
cytes in normal peripheral blood [38,39]. The
complementarity-determining regions of mLL2 were subse-
quently grafted onto a human IgG1 genetic backbone [40].
Epratuzumab, the resulting complementarity-determining
region-grafted (recombinant) 'humanized' monoclonal anti-
body (hLL2), is 90% to 95% of human origin, thus greatly
reducing the potential for immunogenicity. Epratuzumab has
been shown to mediate antibody-dependent cellular cytotoxic-
ity in vitro[41] , and may also exhibit biological activity through
modulating BCR function (J Carnahan, R Stein, Z Qu, K Hess,
A Cesano, HJ Hansen, DM Goldenberg, manuscript submit-
ted).
In clinical trials, over 400 patients with non-Hodgkin lymphoma
(NHL) or other B cell malignancies have received epratuzumab
administered as 4 consecutive weekly infusions over about 60
minutes. An initial phase I/II study administered doses of up to
1,000 mg/m2, with patients premedicated each week with oral
acetaminophen and diphenhydramine to minimize potential
infusion reactions. Epratuzumab toxicity consisted primarily of
mild to moderate transient infusion-related events during the
first infusion, and only one patient with a prior right lung resec-
tion for a fungal abscess had a serious event (bronchospasm
during infusion), which was treated with parenteral medica-
tions. Based on this safety record, objective evidence of tumorAvailable online http://arthritis-research.com/content/8/3/R74
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response, and less severe depression of circulating B cells
[42,43] , 4 consecutive weekly doses of 360 mg/m2 epratuzu-
mab was selected as a sufficiently safe and efficacious treat-
ment regimen to warrant further clinical development. A
pharmacokinetic analysis of weekly dosing subsequently dem-
onstrated that the post-treatment serum half-life of epratuzu-
mab in NHL patients was 19 to 25 days, consistent with the
half-life of a human IgG1 [44]. As such, a longer interval
between doses was indicated, and a biweekly dosing sched-
ule was selected for this initial study in SLE. We report here
the first experience of treating an autoimmune disease with a
CD22 antibody, epratuzumab.
Materials and methods
This initial, phase II, open-label, non-randomized, single-center
study was undertaken to obtain preliminary evidence of thera-
peutic activity in SLE, to confirm the safety, tolerance and lack
of immunogenicity of epratuzumab in this population, and to
evaluate pharmacokinetic and pharmacodynamic parameters.
The study was approved by the Ethics Committee of Charité
University Hospital.
Patient population
Males or non-pregnant, non-lactating females, ≥ 18 years of
age, were eligible to participate provided they had a diagnosis
of SLE according to the American College of Rheumatology
revised criteria (fulfilled ≥ 4 criteria), with SLE for at least 6
months, and at least one elevated autoantibody level (antinu-
clear antibodies/ANA and/or anti-dsDNA) and moderately
active disease (a score of 6 to 12 for total British Isles Lupus
Assessment Group (BILAG) disease activity) at study entry.
Patients were excluded if they had prior rituximab or other anti-
body therapy, allergies to murine or human antibodies, experi-
mental therapy within 3 months, active severe CNS (central
nervous system) lupus, laboratory abnormalities (hemoglobin
< 8.0 g/dl, WBC (white blood cells) < 2,000/mm3, ANC
(absolute neutrophil cells) < 1,500/mm3, platelets < 50,000/
µl, liver transaminases or alkaline phosphatase more than
twice upper limit of normal, serum creatinine > 2.5 mg/dl, or
proteinuria > 3.5 gm/day), thrombosis, drug or alcohol abuse,
infection requiring hospitalization within 3 months, long-term
active infectious diseases (tuberculosis, fungal infections)
within 2 years, malignancy (except basal cell carcinoma, cervi-
cal carcinoma in situ (CIS), history of recurrent abortions (2 or
more), or known HIV, hepatitis B or C, or other immunosup-
pressive states.
Concomitant medications
Pulsed methylprednisolone, other high-dose corticosteroids,
cyclophosphamide, and intravenous, joint, or intramuscular
corticosteroid injections were not allowed during the study or
within four weeks of study entry. Low-dose corticosteroids
(prednisone, = 20 mg/day or equivalent) or background ther-
apy with standard antirheumatic immunosuppressives (for
example, azathioprine, methotrexate) was permitted provided
there were no dosing changes during the study or within four
weeks prior to study entry. Antimalarials, non-steroidal anti-
inflammatory drugs (NSAIDs), ACE-inhibitors or angiotensin
receptor antagonists were also allowed, provided there were
no dosing changes during the study or within two weeks of
study entry.
Treatment schedule
After satisfying eligibility, signing informed consent, and under-
going baseline evaluations, all patients received 4 doses of
360 mg/m2 epratuzumab administered every other week with
paracetamol (acetaminophen) and an antihistamine (but no
steroids) given as premedication prior to each dose.
Study evaluations
The BILAG system was used to categorize the severity level of
lupus disease activity in each patient at study entry and at
post-treatment evaluations obtained at 6 (24 hours after the
last infusion), 10 and 18 weeks and at an additional 32 weeks
(6 month post-treatment) follow-up visit. The BILAG system
organizes lupus-associated signs and symptoms according to
eight body systems: general/constitutional, mucocutaneous,
neurological, musculoskeletal, cardiovascular/respiratory, vas-
culitic, renal, hematological domains [45,46]. At each evalua-
tion, the presence and change of any signs and symptoms
were recorded and the level of any disease activity within each
body system determined on a treatment-intent basis, accord-
ing to BILAG rules as: A (severely active disease sufficient to
require disease-modifying treatment, for example, > 20 mg/d
prednisolone, immunosuppressants/cytoxics); B (moderately
active disease requiring only symptomatic therapy, for example
< 20 mg/d prednisolone, antimalarials, NSAIDs alone or in
combination); or C (stable mild disease with no indication for
changes in treatment). To assign an overall disease activity
level for each patient, a total BILAG score was determined by
adding a numerical severity score (A = 9, B = 3, C = 1, no
activity = 0) across the eight body systems. Other evaluations
at these times included an SLE panel (autoantibodies, C3, C-
reactive protein/CRP, erythrocyte sedimentation rate/ESR,
other laboratory tests), vital signs, physical examination,
adverse events, routine safety laboratory tests (hematology,
serum chemistry), urinalysis, serum immunoglobulins, periph-
eral blood B and T cells, epratuzumab serum levels (analyzed
by sponsor), and human anti-human (epratuzumab) antibody
titers (HAHA; analyzed by sponsor).
Human anti-human (epratuzumab) antibody assay
The sponsor's HAHA test is a competitive ELISA assay, where
the capture reagent is epratuzumab and the probe is an anti-
epratuzumab-idiotype antibody. The anti-idiotype antibody is
an acceptable surrogate for what is reacted against in an
immunogenic response by humans against the binding portion
of epratuzumab that distinguishes the molecule from other
human antibodies (for instance, the framework region that has
human amino acid sequences). Test results are derived fromArthritis Research & Therapy    Vol 8 No 3    Dörner et al.
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an eight-point standard curve with varying dilutions of anti-idi-
otype antibody in bovine serum albumin. Patient serum sam-
ples are diluted 1:2 with bovine serum albumin and assayed in
triplicate. The anti-idiotype standard curve is used to deter-
mine the presence of HAHA in unknown samples. An accept-
able assay is based on linear regression parameters that must
be met to define a valid assay.
Statistical analyses
The primary assessment of disease activity compared post-
treatment BILAG results with those at study entry, using total
BILAG scores for overall assessment and letter grade catego-
ries to assess the level of disease activity within each body
system. Adverse events and safety laboratory tests were
graded according to NCI CTC version 3.0 criteria on a 1 to 4
scale for toxicity (1, mild; 2, moderate; 3, severe; 4, life threat-
ening). All analyses of efficacy, safety, tolerance, immuno-
genicity, pharmacokinetics, and pharmacodynamics used
descriptive statistics. Wilcoxon signed rank test was used to
assess the statistical significance of changes in total BILAG
scores compared to their baseline values. All statistical tests
used a significance level of 0.05.
Results
Demographics and patient characteristics at study entry
A total of 14 Caucasian patients (13 females and 1 male; 23
to 53 years old, median age 40 years) were enrolled. At study
entry, the patients had been initially diagnosed with SLE 1 to
19 years (median 10 years) earlier and were receiving corti-
costeroids (n = 13, 1 to 12 mg/day prednisolone) plus immu-
nosuppressives (n  = 11, including 50 to 200 mg/day
azathioprine, n = 9; 20 mg/day methotrexate, n = 2; 2 g/day
mycophenalate mofetil, n = 1), and antimalarials (n = 6, 200 to
600 mg/day hydroxychloroquine). All patients had positive
ANA at study entry (titers of 80:1 to 5,120:1), and 5 patients
(36%) had positive anti-dsDNA antibody levels (> 10 U/ml).
Ten patients (71%) had ESR values that were elevated (> 15
mm/h) and 4 patients (29%) had raised CRP levels (> 0.5 mg/
dl), while only 3 patients (21%) had C3 levels that were bor-
derline low or decreased (< 90 mg/dl), and no patient had
Table 1
Number of patients with B-level disease activity at study entry 
in each BILAG body system
Body system Number of 
patients
Contributing signs/symptoms* 
(number of patients)
I. General/
constitutional
3 Fatigue/malaise/lethargy (3)
Anorexia/nausea/vomiting (2)
Unintentional weight loss > 5% 
(1)
II. Mucocutaneous 13 Malar erythema (11)
Active localized discoid lesions 
(2)
Mild maculopapular eruption (1)
III. Neurological 0
IV. Musculoskeletal 2 Arthritis (2)
V. CV/Respiratory 2 Dyspnea (2)
Pleuropericardial pain (2)
VI. Vasculitis 5 Minor cutaneous vasculitis 
(nailfold/digital vasculitis, 
purpura, urticaria) (5)
VII. Renal 0
VIII. Hematology 1 Anemia (hemoglobin < 11 g/dL) 
(1)
*Signs and symptoms that contributed to the B-level disease activity 
according to BILAG rules.
Table 2
Number of patients with C-level disease activity at study entry 
in each BILAG body system
Body system Number of 
patients
Contributing signs/symptoms* 
(number of patients)
I. General/
Constitutional
11 Fatigue/malaise/lethargy (10)
Anorexia/nausea/vomiting (1)
Lymphadenopathy/splenomegaly (1)
Pyrexia (documented) (1)
II. 
Mucocutaneous
1 Mild alopecia (1)
III. Neurological 10 Episodic migrainous headaches (8)
Severe, unremitting headache (2)
IV 
Musculoskeletal
11 Arthralgia (10)
Myalgia (9)
Improving arthritis (1)
V. CV/
Respiratory
2D y s p n e a  ( 1 )
Pleuropericardial pain (1)
VI. Vasculitis 4 Raynaud's (3)
Livido reticularis (1)
VII. Renal 4 Mild/stable proteinuria (4)
VIII. Hematology 11 Lymphocytopenia 
(< 1500 cells/µl) (10)
Evidence of circulating 
anticoagulant (1)
Decreased platelets 
(< 150,000/µl) (1)
*Signs and symptoms that contributed to the C-level disease activity 
according to BILAG rules.Available online http://arthritis-research.com/content/8/3/R74
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positive direct Coombs' or serum haptoglobulin levels ele-
vated above borderline.
All patients had total BILAG scores of 6 to 12 (median 10) at
study entry. No patient had A-level disease activity in any body
system, 13 patients had B-level disease activity in at least one
body system (2 with three Bs, 9 with 2 Bs, 2 with one B) and
one patient had only C-level activities. B-level disease
occurred primarily in the mucocutaneous, vasculitis, and gen-
eral/constitutional body systems, with no B-level disease activ-
ity in the neurological or renal systems (Table 1), while C-level
disease occurred primarily in the general/constitutional, musc-
uloskeletal, hematological and neurological body systems
(Table 2). The actual signs and symptoms at study entry that
contributed to the B-level disease activity according to the
BILAG rules are also summarized in Table 1, while those con-
tributing to C-level disease activity are summarized in Table 2.
Study drug administration
Twelve of the 14 patients (86%) completed all 4 infusions of
360 mg/m2 epratuzumab as scheduled, while one patient with
sleepiness attributed to premedication IV antihistamines pre-
maturely terminated the first infusion but subsequently com-
pleted all 3 remaining infusions without further event, and one
patient completed the first two infusions, but discontinued fur-
ther infusions after development of herpes zoster, which
responded to antivirals. The infusions were well tolerated, with
a median infusion time of 32 minutes (23 to 86 minutes), and
with infusion reactions in 6 patients all limited to occurrences
of transient, mild (grade 1 NCI toxicity) adverse events (flu-like
symptoms, tracheitis/throat ache, n  = 2; arthralgia/myalgia,
fever, fatigue, nausea, headache, chills, or rash, n = 1).
Post-treatment evaluations and follow-up
All patients remained in the study through the 18-week post-
treatment evaluation period. One patient had a late 18-week
visit that fell within the 32-week time frame and the corre-
sponding data were hence re-assigned to the 32-week visit.
The single patient who did not complete all 4 infusions contin-
ued to receive post-treatment evaluations beginning at the 10-
weeks follow-up visit. Except for the aforementioned devia-
tions, all patients received post-treatment evaluations at 6, 10,
and 18 weeks. One patient was lost to follow-up after 18
weeks, while 13 patients returned for the final 32-week evalu-
ations (8 patients as scheduled, 5 with a delayed visit between
42 to 82 weeks).
BILAG treatment response
The effect of epratuzumab on clinical manifestations was eval-
uated at 6, 10, and 18 weeks using numerical total BILAG
scores as well as categorical scores. The compositions of B-
and C-level activities improved after treatment, primarily in the
general, mucocutaneous and musculoskeletal systems (Figure
1). Improvement in C-level activity was also observed in the
neurological and renal domains. Improvements in the general,
mucocutaneous, neurological and musculoskeletal systems
occurred earlier compared to the cardiovascular/respiratory,
vasculitic and renal systems (Figure 2). However, the limited
number of patients with manifestations in each of these sys-
tems precludes a definitive determination of preferential
effects. In terms of changes in the total BILAG score, statisti-
cally significant improvement was observed at 6, 10, and 18
weeks (Figure 3). Additionally, a substantial proportion of
patients showed 50% or more improvement in total BILAG
score at weeks 6, 10, and 18 (77%, 71% and 38%, respec-
tively). At the final 32-week evaluation, statistically significant
Figure 1
Frequency comparison of BILAG B- and C-level activities for each body system at screening, 6, 10 and 18 weeks Frequency comparison of BILAG B- and C-level activities for each body system at screening, 6, 10 and 18 weeks.Arthritis Research & Therapy    Vol 8 No 3    Dörner et al.
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improvement in total BILAG score continued to be observed,
with 15% of the patients achieving 50% or more improvement.
In a separate analysis, the total number of patients who
achieved BILAG improvements in the particular domains at 6,
10 and 18 weeks of follow-up are summarized in Table 3. This
indicates that the most characteristic BILAG domains, as also
seen in Figure 2, were more likely to respond, although the
duration of response was very similar throughout the domains.
In fact, deterioration in BILAG categorical scores compared to
baseline was infrequently seen during the study (Table 4).
Only two patients (14%) showed worsening of hematological
parameters (lymphocytopenia), one starting at 6 weeks and
the other at 18 weeks. Another patient manifested renal (mild
proteinuria) deterioration at 10 weeks. Overall, at week 18, 3
patients (21%) had a deteriorated BILAG assessment in at
least one body system compared to baseline.
An additional analysis was performed to determine the durabil-
ity of resolution of certain B- and C-level activities (Table 5).
Although in a number of patients, B- and C-level activities
resolved persistently, the heterogeneity of patients' manifesta-
Figure 2
Overall frequency and mean improvement of total disease activity as  measured by the total BILAG score at 6, 10 and 18 weeks Overall frequency and mean improvement of total disease activity as 
measured by the total BILAG score at 6, 10 and 18 weeks.
Figure 3
Mean time to improvement of each BILAG body stystem Mean time to improvement of each BILAG body stystem. Mean time to improvement (in days) of each BILAG body system during the follow-up of the 
study (N denotes the number of patients available for analysis for each body system). Since the first evaluation was scheduled for 6 weeks, the ear-
liest time to improvement is at least 42 days.
Table 3
Number of patients with improvement from baseline BILAG B- 
and C-level activities
BILAG body system 6 weeksa 10 
weeks
18 
weeks
General (N = 14)b 6 (43%) 5 (36%) 2 (14%)
Mucocutaneous (N = 14) 11 (79%) 8 (57%) 6 (43%)
Neurological (N = 10) 7 (70%) 8 (80%) 6 (60%)
Musculoskeletal (N = 13) 9 (69%) 7 (54%) 4 (31%)
CV/Respiratory (N = 4) 3 (75%) 3 (75%) 3 (75%)
Vasculitis (N = 9) 4 (44%) 3 (33%) 3 (33%)
Renal (N = 4) 2 (50%) 1 (25%) 3 (75%)
Hematology (N = 12) 0 (0 %) 0 (0 %) 0 (0 %)
Overallc (N = 14) 13 (93%) 14 
(100%)
13 
(93%)
aTwenty-four hours after fourth infusion. bN = number of patients with 
involvement in a particular body system at entry. cAs applied to any 
BILAG body system.Available online http://arthritis-research.com/content/8/3/R74
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tions again precluded the identification of a preferential
response profile to the drug.
Safety
During or following treatment, a total of ten patients reported
adverse events. As reported above, six had mild, transient,
infusional reactions and one patient experienced somnolence
following antihistamine medication. Subsequently, five
patients had infections (including herpes zoster, otitis media,
Helicobacter pylori-associated gastritis, vaginitis/vaginal can-
didiasis, cystitis, and tonsillitis) that resolved with appropriate
treatment, and one patient had spinal contusion from a traffic
accident. Standard safety laboratory tests showed no consist-
ent pattern of change from baseline, and infrequent post-treat-
ment increases in NCI CTC v3.0 toxicity grades for these
laboratory tests were all limited to changes of one grade level
except for one patient with an increase in lymphocytes from
grade 1 to grade 3, and another from grade 0 to grade 3
(Table 6).
Pharmacokinetics and immunogenicity
Of the 14 patients, serum samples for analysis of pharmacok-
inetics and immunogenicity (HAHA) by ELISA assay were col-
lected in a limited number of patients post-treatment at 6
weeks (n = 12), 10 weeks (n = 7) and 18 weeks (n = 7).
Epratuzumab serum levels were measurable in all available
samples through at least 10 weeks post-treatment and were
still detectable above the 0.5 µg/ml assay limit in 5/7 samples
evaluated at 18 weeks, with median values of 120 µg/ml
(range 49 to 350) at 6 weeks, 48 µg/ml (range 31 to 138) at
10 weeks, and 8.3 µg/ml (range 1.82 to 25) at 18 weeks. Fig-
ure 4 shows the individual measurements over time. There was
a single sample showing 1.42 µg/ml at 32 weeks. HAHA anal-
ysis gave no evidence of immunogenicity, with all post-treat-
ment values either remaining below the 50 ng/ml sensitivity of
the assay or not increased from baseline values prior to treat-
ment.
Immunology laboratory tests
Table 7 shows that at the first evaluation after treatment, mean
B cell levels decreased by 35% and persisted at these levels
on subsequent evaluations (Figure 5), with no evidence of
onset of recovery by the final study evaluation at 32 weeks (6
months post-treatment). In contrast, there does not appear to
be any consistent pattern of decreases/increases in T cell lev-
els or serum levels of IgG, IgA, or IgM following treatment
(Table 7).
Although all 14 patients had measurable ANA titers (1:80 to
1:5,120) at study entry, no patient had consistent post-treat-
ment decreases, including evaluations at 32 weeks (6 months
post-treatment) follow-up (8 patients had no changes at any
evaluation, 5 doubled their baseline titers at one or more eval-
uations, and one patient had an isolated decrease at one eval-
uation). Five patients had elevated anti-dsDNA antibodies (10
to 123 U/ml) at study entry, but none had any decreased post-
treatment values (2 patients had no significant changes, and 3
had increases at one or more evaluations). C3 levels that were
decreased or borderline for 3 patients at study entry remained
virtually unchanged post-treatment, as did mean C3 values for
all patients.
Table 4
Number of patients with deteriorating BILAG activities from 
baseline
BILAG body system (N = 14)a 6 weeksb 10 weeks 18 weeks
General 0 (0 %) 0 (0 %) 0 (0 %)
Mucocutaneous 0 (0 %) 0 (0 %) 0 (0 %)
Neurological 0 (0 %) 0 (0 %) 0 (0 %)
Musculoskeletal 0 (0 %) 0 (0 %) 0 (0 %)
CV/Respiratory 0 (0 %) 0 (0 %) 1 (7 %)
Vasculitis 0 (0 %) 0 (0 %) 0 (0 %)
Renal 0 (0 %) 1 (7 %) 0 (0 %)
Hematology 1 (7 %) 1 (7 %) 2 (14%)
Overallc 1 (7 %) 2 (14%) 3 (21%)
aN = total number of patients. bTwenty-four hours after fourth 
infusion. cAs applied to any BILAG body system.
Table 5
Number of patients in each BILAG body system with resolution 
of baseline B- and C-level disease activities
Body system B level C level
General 3/3 (100%) 0/11 (0%)
Mucocutaneous 4/13 (31%) 0/1 (0%)
Neurological 0/0 2/10 (20%)
Musculoskeletal1 /2 (50%) 1/11 (9%)
CV/Respiratory 0/2 (0%) 2/2 (100%)
Vasculitis 2/5 (40%) 0/4 (0%)
Renal 0/0 2/4 (50%)
Hematology 0/1 (0%) 0/11 (0%)
Resolution is defined as post-treatment improvement of baseline 
disease activity level by at least one category level (B to C, D, or E; C 
to D or E) at one or more evaluations up to 18 weeks, with no 
categorical deterioration from the baseline activity level prior to 
improvement, and no reversion to the baseline activity level once any 
improvement has occurred. Additionally note that 3 patients with 
multiple BILAG B involvement at baseline had completely resolved all 
B-level disease activities by 18 weeks.Arthritis Research & Therapy    Vol 8 No 3    Dörner et al.
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Discussion
The pathogenesis of SLE remains enigmatic, but a central fea-
ture of this disease is the loss of immune tolerance and
enhanced B cell activity. Although the number of B cells in the
peripheral blood is often decreased, those that are present
show characteristic alterations and have abnormal pheno-
types indicative of activation [5,47]. Therefore, B cell depletion
is an attractive therapeutic strategy for patients with SLE. The
availability of the chimeric anti-CD20 antibody rituximab
(Rituxan® Genentech, South San Francisco, CA, USA; Biogen
Idec, Boston, MA, USA) made it possible to test this hypothe-
sis.
Initially, Isenberg and coworkers [19] treated 6 patients with
active and otherwise refractory SLE (median BILAG score 14,
range 9 to 27) with rituximab given in 500 mg doses 2 weeks
apart with 2 doses of 750 mg iv cyclophosphamide and oral
prednisolone cover (30 or 60 mg for 5 days). The treatment
was safe and well tolerated, B cell depletion occurred, and
BILAG total scores improved at 6 months (median 6, range 3
to 8). Looney and colleagues [6] initiated an open-label rituxi-
mab study of 17 patients with SLE (≥ 6 systemic lupus activity
measurement, SLAM score) who were treated with either one
100 mg/m2 dose, one 375 mg/m2 dose, or four 375 mg/m2
doses. Oral prednisone (40 mg for two doses) also was
administered. B cell decreases were variable, with a 35%
mean decrease persisting over the 6-month observation
period, and clinical efficacy was demonstrated in patients with
B cell depletion. Less than 6/17 of their patients developed
human anti-chimeric antibody (HACA) at a level higher than or
equal to 100 ng/ml when treated with this protocol.
All of these studies and case reports have so far been of short
duration [7,48]. Usually, the B cell depletion in SLE is pro-
found, as in patients with NHL, but shorter lasting. Therefore,
it is very likely that cyclical therapy will be needed to provide
long-term benefit for patients with SLE. While the immuno-
genicity of rituximab has not been clinically important (HACA
< 1%) for the management of patients with NHL, approxi-
mately 4% of patients with rheumatoid arthritis developed
HACA and 8% to 10% with SLE did so also, in spite of being
Table 6
Post-treatment increases in NCI CTC v3.0 toxicity grades from 
baseline values
Labparameter No increase Toxicity increase
1 grade 2–3 grades
Hematology
Hemoglobin 10 4 0
Platelets 12 2 0
WBC 11 3 0
ALC 6 6 2
ANC 13 1 0
Chemistry
Creatinine 10 4 0
Total Bilirubin 14 0 0
Alkaline 
phosphatase
12 2 0
ALT (SGPT) 9 5 0
AST (SGOT) 10 4 0
GGT 12 2 0
ALC, absolute lymphocyte count, ANC, absolute neutrophil count, 
ALT, alanine aminotransferase, AST, aspartate aminotransferase, 
GGT, gamma glutamyl transferase, WBC, white blood cell
Figure 4
Serum levels of epratuzumab as detected by ELISA in the patients dur- ing the study Serum levels of epratuzumab as detected by ELISA in the patients dur-
ing the study.
Figure 5
Follow-up of peripheral B cell levels during the study among individual  study patients Follow-up of peripheral B cell levels during the study among individual 
study patients.Available online http://arthritis-research.com/content/8/3/R74
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treated with various doses of steroids and/or cytotoxic agents
in combination with rituximab. Thus, a less immunogenic anti-
body (for example, a human or humanized form) is likely
needed in the management of patients with autoimmune dis-
eases, since it is expected that repeated dosing will be
required in patients with such chronic diseases.
This initial study demonstrated that 360 mg/m2 epratuzumab,
a humanized CD22-specific monoclonal antibody, adminis-
tered every other week for a total of 4 doses was safe and well-
tolerated in SLE patients, with few significant adverse events,
alterations of standard safety laboratory tests, and no evidence
of immunogenicity. In addition to the minimal infusion reac-
tions, the ability to complete an infusion within approximately
0.5 to 1 hour and the lack of immunogenicity are also likely to
be more important treatment considerations in autoimmune
diseases, as mentioned previously.
With this dosing schedule, virtually every patient with moder-
ate disease activity (total BILAG score of 6 to 12) demon-
strated symptomatic improvement using BILAG total scores.
The BILAG total score results indicate that 77% of the
patients achieved a ≥ 50% decrease in their overall disease
activity at 6 weeks follow up. Furthermore, most patients
(92%) continued to show reduced disease activity for at least
18 weeks, and even 38% showed a sustained response with
BILAG reductions of 50% or more compared to study entry.
Since this first study considered moderately active lupus
patients with BILAG total scores of 6 to 12, the resulting het-
erogeneity precludes the identification of any preferential
effect on one or the other BILAG domains as shown from dif-
ferent perspectives of efficacy analysis.
In addition to treating mild BILAG C-level symptoms, epratuzu-
mab immunotherapy reduced all BILAG B-level activity in the
majority of patients presenting with more serious disease,
including patients with B-level activity in several body systems.
The current data limit the conclusions that can be drawn
regarding therapeutic effects for some systems, such as B-
level disease in the neurological and renal systems, and only
one case of lymphopenia in the hematological system showed
improvement. In spite of small numbers, CD22-immuno-
therapy with epratuzumab appeared to be effective for treating
disease in many of the other body/organ systems.
Although the biweekly dosing schedule used in this study
demonstrated apparent activity, the serum levels of antibody
measured here appear to be less than those in studies of NHL,
where a weekly schedule of dose administrations has shown
antitumor activity [42-44]. Hence, other dosing schedules in
future clinical trials are warranted to assess the effects of
increasing the serum levels of epratuzumab.
Compared to the complete depletion of B cells observed with
rituximab, a long-lasting (at least 6 months, the last observation
time) decrease of about 35% to 40% occurred with epratuzu-
mab, with no apparent changes in T cells or immunoglobulin
levels. As discussed earlier, the attractiveness of CD22 as a
molecular target for therapy in SLE extends beyond the capa-
bility of epratuzumab to modestly decrease peripheral blood
levels of B cells. CD22 is a cell surface receptor that is a mem-
ber of the sialioadhesion family and an inhibitory co-receptor of
BCR [34]. In vitro studies demonstrated that epratuzumab
binding can induce CD22 phosphorylation [49] , and the cur-
rent data from this study suggest that epratuzumab could
potentially mediate direct pharmacological effects by nega-
tively regulating certain hyperactive B cells. This hypothesis
now needs to be tested. Interestingly, over the period of this
study, patients clinically improved without clear evidence of
reduction in ANA or anti-dsDNA titers. Similar observations
have been reported with rituximab [19] , further supporting the
hypothesis that targeted therapy impacting the hyperactive B
cell compartment may be successful without needing to com-
pletely deplete the broader B cell population.
Table 7
Post-treatment changes of lymphocytes and immunoglobulins
Baseline values and post-treatment percent change from baseline (mean ± SD)
Baseline 6 weeks 10 weeks 18 weeks 32 weeks
Lymphocytes N = 14 N = 6 N = 8 N = 9 N = 11
B cells 123 ± 160 cells/µl -35% ± 23% -41% ± 41% -34% ± 23% -44% ± 21%
T cells 744 ± 554 cells/µl +16% ± 80% +28% ± 78% +47% ± 109% +17% ± 69%
Immunoglobulins N = 12 N = 14 N = 10 N = 11
IgG 1,252 ± 355 mg/dl +3% ± 8% +5% ± 13% +5% ± 9% 1% ± 13%
IgA 226 ± 94 mg/dl +3% ± 11% +8 ± 13% +5% ± 12% +10% ± 20%
IgM 117 ± 73 mg/dl -12% ± 18% -1% ± 23% -6% ± 19% -9% ± 9%
SD, standard deviation.Arthritis Research & Therapy    Vol 8 No 3    Dörner et al.
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Conclusion
This initial experience in lupus patients with mild to moderate
symptoms demonstrated that 4 doses of 360 mg/m2 epratuzu-
mab immunotherapy are safe and well tolerated when infused
within one hour, with consistent improvement observed in all
patients for at least 12 weeks in the presence of modestly
decreased (about 35%) peripheral B cell levels, and with no
evidence of HAHA. Although this was an open-label study,
consistent improvement was observed in all patients for at
least 12 weeks, and there was reduction or elimination of dis-
ease activity across most body systems, regardless of the
extent or the severity of the presenting disease activity. The
duration of response was very heterogeneous for different
BILAG domains, precluding firm conclusions at this time. As
such, these results support conducting longer-term multi-
center randomized controlled studies, which are now under-
way to examine the effects of epratuzumab in broader patient
populations with autoimmune disease.
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